Document 0003
 DOCN  M9620003
 TI    Oral 2-chlorodeoxyadenosine in psoriatic arthritis. A preliminary
       report.
 DT    9602
 AU    Eibschutz B; Baird SM; Weisman MH; Amox DG; Spellman M; Piacquadio D;
       Carrera CJ; Carson DA; University of California, San Diego, La Jolla,
       USA.
 SO    Arthritis Rheum. 1995 Nov;38(11):1604-9. Unique Identifier : AIDSLINE
       MED/96062434
 AB    OBJECTIVE. To determine if weekly oral 2-chlorodeoxyadenosine (2-CdA)
       can induce selective lymphocytopenia, and reduce inflammation, in
       patients with refractory psoriatic arthritis. METHODS. Seven patients
       with psoriatic arthritis were treated with oral 2-CdA at weekly dosages
       of 0.3 mg/kg to 0.45 mg/kg for 12 weeks, followed by monthly maintenance
       therapy. The patients were evaluated after 6 months. RESULTS. The drug
       treatment produced selective lymphocytopenia, and reduced lymphocyte
       infiltration into involved skin. One patient did not complete 12 weeks
       of therapy because of perceived lack of efficacy. Four of the 6
       remaining patients had improved joint disease, and 5 of 6 had improved
       psoriasis. CONCLUSION. Weekly oral 2-CdA appears to be a well-tolerated
       regimen for the inducement of peripheral lymphocytopenia in patients
       with psoriatic arthritis. Larger-scale, controlled trials may be
       warranted.
 DE    Administration, Oral  Adult  Aged  Arthritis, Psoriatic/BLOOD/*DRUG
       THERAPY/PATHOLOGY  Biopsy  Cladribine/*ADMINISTRATION & DOSAGE  CD4-CD8
       Ratio  Female  Human  Lymphocyte Count/DRUG EFFECTS  Male  Middle Age
       Patient Compliance  Support, U.S. Gov't, P.H.S.  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).